Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $11.80 Consensus PT from Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $11.80.

A number of analysts have weighed in on CMPX shares. Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Finally, D. Boral Capital reiterated a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th.

Compass Therapeutics Stock Up 4.0 %

Compass Therapeutics stock opened at $2.60 on Friday. The business has a fifty day moving average of $1.62 and a two-hundred day moving average of $1.50. The firm has a market cap of $357.73 million, a P/E ratio of -7.03 and a beta of 0.92. Compass Therapeutics has a twelve month low of $0.76 and a twelve month high of $2.70.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Equities analysts expect that Compass Therapeutics will post -0.35 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rovin Capital UT ADV acquired a new stake in Compass Therapeutics during the 3rd quarter worth about $25,000. Intech Investment Management LLC acquired a new stake in Compass Therapeutics during the 3rd quarter worth about $30,000. XTX Topco Ltd acquired a new stake in Compass Therapeutics during the 3rd quarter worth about $37,000. SG Americas Securities LLC grew its position in Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after purchasing an additional 5,515 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in Compass Therapeutics during the 2nd quarter worth about $41,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.